Day: June 19, 2020

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.Financial results for the first quarter of 2020Revenue for the first quarter of 2020 was $0.8 million, compared to $1.8 million for the first quarter of 2019. Net loss for the first quarter of 2020 was $5.3 million, compared to $8.3 million for the first quarter of 2019. Net loss per share for the first quarter of 2020 was $0.68, compared to $3.59 for the first quarter of 2019.Cost of revenue was $0.5 million for the first quarter of 2020, down from $1.2 million for the first quarter of...

UAB Ignitis Grupė, (hereinafter – Ignitis Grupė or the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 900 000 000 EUR; ISIN codes XS1646530565; XS1853999313; XS2177349912.On June 19, 2020 the Supervisory Board of the Company approved updated long-term corporate strategy (hereinafter – the Strategy) of Ignitis Group (hereinafter – the Group) and strategic plan for the period 2020–2023.The Strategy update follows the renewed letter of expectations from the Company’s sole shareholder–Ministry of Finance of the Republic of Lithuania. This letter is published on the website of the Company, at https://ignitisgrupe.lt/en/shareholders.Commitment to the decarbonisation, the modernization of the energy system, the development of renewable...

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 900 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313; XS2177349912.2020 m. birželio 19 d. Bendrovės stebėtojų taryba patvirtino atnaujintą ilgalaikę „Ignitis grupės“ įmonių grupės (toliau – Grupė) veiklos strategiją (toliau – Strategija) ir 2020–2023 m. laikotarpio strateginį planą.Strategijos atnaujinimas paremtas atnaujintu akcininko lūkesčių raštu, kurį Bendrovei pateikė jos vienintelio akcininko teises įgyvendinanti Lietuvos Respublikos finansų ministerija. Su šiuo raštu galima susipažinti Bendrovės svetainėje, adresu: https://www.ignitisgrupe.lt/lt/akcininkai.Didžiausias dėmesys įgyvendinant atnaujintą Grupės strategiją...

RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time.This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary...

VAN NUYS, Calif., June 19, 2020 (GLOBE NEWSWIRE) — Eco Innovation Group, Inc.  (“ECOX” or the “Company”) (OTC: ECOX), an innovative company aggregating investments in new technologies that are environmentally friendly, promote green energy and are socially responsible, announced today that it is moving from Stage 3 testing for its latest energy saving innovation called PoolCooled™.ECOX uses a 9 Step Process to Market Successfully determine if a new product merits acceptance by the Company:Idea GenerationIdea ScreeningConcept Development and TestingMarket Strategy DevelopmentBusiness AnalysisProduct licensing and/or deal structure with the inventor/innovatorProduct DevelopmentTest Marketing/PromotionCommercializationThe PoolCooled™ product utilizes proprietary technologies to take cool water from an existing...

Key PointsImmuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral therapeutic targeting Campylobacter and ETEC for clinical evaluationVaccination program initiatedNMRC submits Pre-Investigational New Drug (IND) information package to FDANMRC plans to file an IND application with FDATwo human phase II clinical trials to be conducted in 2021One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosisThe second trial will focus on ETEC infectionsMELBOURNE, Australia, June 19, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics...

SAN DIEGO, 19 juin 2020 (GLOBE NEWSWIRE) — Crown Bioscience a annoncé aujourd’hui la tenue de sa conférence et son salon commercial innovants AACR 2020. L’événement virtuel, qui se déroulera du 22 au 25 juin, intègrera toutes les caractéristiques d’une conférence scientifique majeure, avec des intervenants principaux, un accès aux affiches AACR 2020 de CrownBio, ainsi qu’un stand au salon commercial.Pour coïncider avec la 2e réunion annuelle virtuelle de l’AACR, ce forum unique comprendra la publication des 13 affiches internes et collaboratives de CrownBio pour l’AACR 2020, couvrant une variété de sujets portant sur l’oncologie préclinique et l’immuno-oncologie, notamment les organoïdes tumoraux et l’ingénierie organoïde, l’imagerie syngénique et les homogreffes des tumeurs,...

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Crown Bioscience hat heute seine innovative AACR 2020 Konferenz und Messe angekündigt. Die virtuelle Veranstaltung vom 22. bis 25. Juni bietet alles, was eine große wissenschaftliche Konferenz auch zu bieten hat: Keynote-Speaker, Zugang zu AACR 2020 Postern von CrownBio sowie einen Messestand.Auf diesem einzigartigen Forum, das gleichzeitig mit dem AACR Virtual Annual Meeting II stattfindet, werden 13 interne und gemeinschaftliche AACR 2020 Poster von CrownBio veröffentlicht. Diese decken eine Reihe von präklinischen Onkologie- und Immunonkologie-Themen ab: Tumor-Organoide und Organoid Engineering, syngene Bildgebung und Tumor-Homografts sowie neuartige humanisierte Wirkstoffzielmodelle. Zudem können die Posterautoren alle Fragen der Teilnehmer direkt beantworten.Die Teilnahme an der Veranstaltung...

聖地牙哥, June 19, 2020 (GLOBE NEWSWIRE) — Crown Bioscience 今天宣佈即將舉行創新的 AACR 2020 會議和貿易展覽會。於 6 月 22 日至 25 日舉行的虛擬活動將涵蓋主要科學會議的所有功能，並安排主題講者、CrownBio 的 AACR 2020 海報及貿易展位。為與第二屆 AACR 虛擬年會配合，此獨特論壇將展示 CrownBio 出版 13 份內部和協作式 AACR 2020 海報，主題包括一系列臨床前腫瘤學，而免疫腫瘤學主題則包括腫瘤類器官和類器官工程、造影同基因和腫瘤同種異體移植，以及創新個人化藥物標靶模型，更邀請海報作者為所有代表解答提問。活動免費參加，但需預先在 CrownBio.com/AACR20上登記。Keynote Theater 的亮點包括由 CrownBio 首席科學總監 Henry Li 博士發表關於採用患者衍生類器官 (PDO) 加速藥物發現的演講，而其他演講將討論生物標記物發現、將 虛擬篩選 應用到體外藥物發現，以及免疫療法毒理學評估平台。CrownBio 市場營銷執行總監 Gavin Cooper 說：「即使我們在全球各地面臨挑戰，但我們仍致力推動科學討論和藥物發現。我們創新的活動體驗旨在實時提供我們所有資源、海報和科學團隊，盡量充分模仿實地會議帶來的體驗。」活動還設有一個科學休息室，以便參與者向科究人員發問和進行實時討論。貿易展位可提供一系列廣泛的 CrownBio 資源，展示大量產品和服務，包括類器官、生物標記物發現、生物資訊學和患者衍生異種移植 (PDX) 模型。活動現己接受免費登記：CrownBio.com/AACR20。關於 Crown Bioscience Inc.Crown Bioscience 是一家 JSR 生命科學公司，是一家全球藥物研發和開發服務公司，提供轉化平台以推進腫瘤學、炎症和代謝疾病研究。憑著廣泛的相關模型和預測工具組合，Crown...

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Crown Bioscience hari ini mengumumkan penyelenggaraan konferensi dan pameran dagang AACR 2020 yang inovatif. Acara yang akan diselenggarakan secara virtual pada 22-25 Juni mendatang ini menghadirkan konferensi sains esensial dengan pembicara utama, akses ke poster AACR 2020 dari CrownBio, serta stan pameran dagang.Bertepatan dengan Rapat Tahunan Virtual AACR yang kedua, forum unik ini akan menampilkan publikasi 13 poster AACR 2020, baik internal maupun kolaboratif, yang mencakup sejumlah topik onkologi dan imuno-onkologi praklinis, meliputi organoid tumor dan rekayasa organoid, pencitraan singeneik dan homograf tumor, serta model target pengobatan manusia yang baru, lengkap dengan poster dari penulis berisi informasi lengkap yang akan dibagikan kepada peserta.Acara ini gratis. Pendaftaran...